Overview

Bioequivalence Trial to Prove Equal Blood Concentrations of Two Different Fluconazole Formulations

Status:
Completed
Trial end date:
2012-09-10
Target enrollment:
Participant gender:
Summary
Primary Objective: To compare the bioavailability of a single dose of fluconazole 150 mg capsules (Test product) with the bioavailability of a single dose of Diflucan™ capsules, 150 mg (Reference) administered under fasting conditions in order to assess bioequivalence Secondary Objectives: To assess safety and tolerability in form of adverse events and clinical parameters (systolic/diastolic blood pressure, pulse rate, body temperature, physical examination, electrocardiogram, clinical laboratory testing, and overall tolerability) and to assess further pharmacokinetic parameters of fluconazole
Phase:
Phase 1
Details
Lead Sponsor:
Bayer
Treatments:
Fluconazole